These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid. Johnson AL; Price WA; Wong PC; Vavala RF; Stump JM J Med Chem; 1985 Nov; 28(11):1596-602. PubMed ID: 2999393 [TBL] [Abstract][Full Text] [Related]
30. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action. Fournie-Zaluski MC; Coric P; Thery V; Gonzalez W; Meudal H; Turcaud S; Michel JB; Roques BP J Med Chem; 1996 Jun; 39(13):2594-608. PubMed ID: 8691458 [TBL] [Abstract][Full Text] [Related]
31. Synthesis and structure-activity relationships of potent new angiotensin converting enzyme inhibitors containing saturated bicyclic amino acids. Blankley CJ; Kaltenbronn JS; DeJohn DE; Werner A; Bennett LR; Bobowski G; Krolls U; Johnson DR; Pearlman WM; Hoefle ML J Med Chem; 1987 Jun; 30(6):992-8. PubMed ID: 3035180 [TBL] [Abstract][Full Text] [Related]
32. Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats. Sweet CS; Arbegast PT; Gaul SL; Blaine EH; Gross DM Eur J Pharmacol; 1981 Dec; 76(2-3):167-76. PubMed ID: 6174351 [TBL] [Abstract][Full Text] [Related]
33. [Synthesis and biological activity of some Val(Ala)-Tyr and Val-Tyr-Tyr peptides]. Chen PL; Peng SX; Yang ZX Yao Xue Xue Bao; 1992; 27(12):895-902. PubMed ID: 1299138 [TBL] [Abstract][Full Text] [Related]
34. Attenuation of pressor responses to intracerebroventricular angiotensin I by angiotensin converting enzyme inhibitors and their effects on systemic blood pressure in conscious rats. Baum T; Becker FT; Sybertz EJ Life Sci; 1983 Mar; 32(12):1297-303. PubMed ID: 6300578 [TBL] [Abstract][Full Text] [Related]
35. Human angiotensin I competes with two non-thiol converting enzyme inhibitors (CGS 13934 & MK-422) to inhibit the angiotensin-converting enzyme activity of human plasma. Chen DS; Nussberger J; Brunner HR; Waeber B J Pharm Pharmacol; 1984 Oct; 36(10):707-8. PubMed ID: 6150096 [TBL] [Abstract][Full Text] [Related]
36. Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors. Robl JA; Cimarusti MP; Simpkins LM; Brown B; Ryono DE; Bird JE; Asaad MM; Schaeffer TR; Trippodo NC J Med Chem; 1996 Jan; 39(2):494-502. PubMed ID: 8558518 [TBL] [Abstract][Full Text] [Related]
37. Angiotensin converting enzyme inhibitors: spirapril and related compounds. Smith EM; Swiss GF; Neustadt BR; McNamara P; Gold EH; Sybertz EJ; Baum T J Med Chem; 1989 Jul; 32(7):1600-6. PubMed ID: 2544729 [TBL] [Abstract][Full Text] [Related]
38. Ketomethyldipeptides I. A new class of angiotensin converting enzyme inhibitors. Natarajan S; Gordon EM; Sabo EF; Godfrey JD; Weller HN; Pluscec J; Rom MB; Cushman DW Biochem Biophys Res Commun; 1984 Oct; 124(1):141-7. PubMed ID: 6093782 [TBL] [Abstract][Full Text] [Related]
39. A comparison of inhibition of angiotensin I conversion by three converting enzyme inhibitors in rats. Takata Y; Di Nicolantonio R; Hutchinson JS Clin Exp Pharmacol Physiol Suppl; 1982; 7():129-34. PubMed ID: 6183035 [TBL] [Abstract][Full Text] [Related]